PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jrsocmedLink to Publisher's site
 
J R Soc Med. 1985 November; 78(11): 899–905.
PMCID: PMC1289996

Practical applications of a monoclonal antibody (NDOG2) against placental alkaline phosphatase in ovarian cancer.

Abstract

A monoclonal antibody (NDOG2) against placental alkaline phosphatase (PLAP) in ovarian cancer has been used in three ways by the Bristol University Department of Obstetrics & Gynaecology. First, in an indirect immunoperoxidase technique, NDOG2 demonstrated positive standing in 64% of 56 ovarian carcinomas as well as in 25% of 44 benign tumours. The majority of these positive tumours were serous cystadenocarcinomas or serous cystadenomas and there was considerable variation in the expression of this antigen from tumour to tumour. NDOG2 was also used as the basis of two serum assays and, when labelled with 123-iodine (123I), in radioimmunoscintigraphy (RIS) to monitor patients' response to therapy. The first serum assay measures the enzymic activity of PLAP and the second recognizes the antigenicity of the molecules. Assay 2 proved more useful in that it predicted the course of the disease in 45% of patients followed up, whereas Assay 1 was only of use in 25% of cases. RIS proved to be a useful imaging technique and was at least as sensitive as conventional imaging techniques. The common causes of false-positive and false-negative results are described.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.5M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Bast RC, Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981 Nov;68(5):1331–1337. [PMC free article] [PubMed]
  • Burrows S. Serum enzymes in the diagnosis of ovarian malignancy. Am J Obstet Gynecol. 1980 May 1;137(1):140–141. [PubMed]
  • Doellgast GJ, Homesley HD. Placental-type alkaline phosphatase in ovarian cancer fluids and tissues. Obstet Gynecol. 1984 Mar;63(3):324–329. [PubMed]
  • Epenetos AA, Britton KE, Mather S, Shepherd J, Granowska M, Taylor-Papadimitriou J, Nimmon CC, Durbin H, Hawkins LR, Malpas JS, et al. Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours. Lancet. 1982 Nov 6;2(8306):999–1005. [PubMed]
  • Haije WG, Meerwaldt JH, Talerman A, Kuipers T j, Baggerman L, Teeuw AH, van der Pompe WB, van Driel J. The value of a sensitive assay of carcino-placental alkaline phosphatase (CPAP) in the follow-up of gynecological cancers. Int J Cancer. 1979 Sep 15;24(3):288–293. [PubMed]
  • Higashino K, Hashinotsume M, Kang KY, Takahashi Y, Yamamura Y. Studies on a variant alkaline phosphatase in sera of patients with hepatocellular carcinoma. Clin Chim Acta. 1972 Aug;40(1):67–81. [PubMed]
  • McLaughlin PJ, Gee H, Johnson PM. Placental-type alkaline phosphatase in pregnancy and malignancy plasma: specific estimation using a monoclonal antibody in a solid phase enzyme immunoassay. Clin Chim Acta. 1983 May 30;130(2):199–209. [PubMed]
  • Sell A, Sogaard H, Norgaard-Pedersen B. Serum alpha-fetoprotein as a marker for the effect of post-operative radiation therapy and/or chemotherapy in eight cases of ovarian endodermal sinus tumour. Int J Cancer. 1976 Nov 15;18(5):574–580. [PubMed]
  • Stolbach LL, Krant MJ, Fishman WH. Ectopic production of an alkaline phosphatase isoenzyme in patients with cancer. N Engl J Med. 1969 Oct 2;281(14):757–762. [PubMed]
  • Sunderland CA, Davies JO, Stirrat GM. Immunohistology of normal and ovarian cancer tissue with a monoclonal antibody to placental alkaline phosphatase. Cancer Res. 1984 Oct;44(10):4496–4502. [PubMed]
  • Umbach G. Review of tumor markers for ovarian cancer. Med Hypotheses. 1984 Mar;13(3):329–339. [PubMed]
  • van Nagell JR, Jr, Donaldson ES, Hanson MB, Gay EC, Pavlik EJ. Biochemical markers in the plasma and tumors of patients with gynecologic malignancies. Cancer. 1981 Jul 15;48(2 Suppl):495–503. [PubMed]
  • Warnock ML, Reisman R. Variant alkaline phosphatase in human hepatocellular cancers. Clin Chim Acta. 1969 Apr;24(1):5–11. [PubMed]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press